Med Page Today
SEPTEMBER 4, 2024
(MedPage Today) -- Health professionals often perform the "eyeball test" when they first meet a patient. Through the power of observation, pixels of information are gathered quickly and often unconsciously to determine whether a patient is unwell.
HCPLive
SEPTEMBER 4, 2024
Rizk discusses the recent FDA accelerated approval of iptacopan (Fabhalta) and reflects on the significance of other therapeutic developments in IgAN.
Science Daily - Heart Disease
SEPTEMBER 4, 2024
A new study has found that regular mobile phone use was positively associated with incident cardiovascular diseases risk. In addition, this association was partly attributed to poor sleep, psychological distress, and neuroticism.
HCPLive
SEPTEMBER 4, 2024
An expert on fibromyalgia discusses concerns associated with long-term use of medications.
NEJM Journal Watch - Cardiology
SEPTEMBER 4, 2024
Invasive and conservative strategies had similar outcomes in a randomized trial involving patients age 75 years or older with non–ST-segment elevation myocardial infarction.
The New England Journal of Medicine
SEPTEMBER 4, 2024
In a 57-year-old man with chest pain, an ECG obtained by EMS showed widespread ST-segment depressions. At the hospital, left main coronary-artery stenosis was seen on angiography (shown in a video).
Science Daily - Heart Disease
SEPTEMBER 4, 2024
Our risk of developing atherosclerosis -- 'furring' of the arteries -- can begin much earlier in life than was previously thought, highlighting the need to keep cholesterol levels low even when we are young, new research has discovered.
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
American College of Cardiology
SEPTEMBER 4, 2024
The following are key points to remember from a state-of-the-art review on management of patients with coexisting atrial fibrillation (AF) and heart failure with reduced ejection fraction (HFrEF).
HCPLive
SEPTEMBER 4, 2024
Ahmad Masri, MD, MS, discusses the results of a SEQUOIA-HCM substudy leveraging cardiac magnetic resonance to assess structural changes associated with aficamten use in HCM.
Journal of Cardiothoracic Surgery
SEPTEMBER 4, 2024
Type A acute aortic dissection (TAAAD) is a deadly condition that demands immediate surgery, because it involves a critically. The mortality and morbidity associated with it are significant, and it is vital th.
HCPLive
SEPTEMBER 4, 2024
Ahmad Masri, MD, MS, highlights a trio of studies from ESC Congress 2024 examining use of aficamten in hypertrophic cardiomyopathy.
CardiacWire
SEPTEMBER 4, 2024
Nearly a year after Bayer halted its OCEANIC-AF trial , the study’s ESC 2024 presentation revealed new insights into asundexian’s AFib stroke-prevention challenges and what they might mean for Factor XI inhibitors. Factor XI/XIa inhibitors have sparked optimism for their potential to become safer antithrombotics by avoiding anticoagulants’ bleeding risks.
DAIC
SEPTEMBER 4, 2024
tim.hodson Wed, 09/04/2024 - 16:08 Sept. 1 — September is Peripheral Artery Disease (PAD) Awareness Month, a time to educate and empower people to act against the most debilitating disease they haven’t heard of — or know that they have. PAD affects more than 10 million Americans and is a factor in 400 amputations each day, making it the largest cause of nontraumatic amputations in the United States.
Becker's Hospital Review - Cardiology
SEPTEMBER 4, 2024
An AI-enabled stethoscope identified heart failure in two times as many pregnant patients when compared to traditional screening, according to a study published Sept. 2 in Nature Medicine.
DAIC
SEPTEMBER 4, 2024
tim.hodson Wed, 09/04/2024 - 15:53 Sept. 1, 2024 — Researchers at UTHealth Houston have identified genetic variants linked to a rare form of bicuspid aortic valve disease that affects young adults and can lead to dangerous and potentially life-threatening aortic complications. The study was published in the American Journal of Human Genetics. “We previously found that young individuals who present due to early onset thoracic aortic dissections are more likely to have bicuspid aortic valves and
HCPLive
SEPTEMBER 4, 2024
Panelists discuss how treating hypercortisolism in patients may have long-term effects on glycemic control and overall health, potentially influencing future standards of care for difficult-to-control Type 2 diabetes, while emphasizing the need for clinicians to carefully manage such patients as ongoing research continues.
Physiologically Speaking
SEPTEMBER 4, 2024
Greetings! David Roche is a decorated trail runner, coach, and co-founder of SWAP Running. He's a two-time national champion and a three-time Team USA member, and he recently set the course record at the Leadville 100 trail run with a time of 15 hours, 26 minutes, 34 seconds. David and his wife, Megan Roche, M.D., offer coaching that blends science, training theory, and a philosophy of joy and long-term growth for all athletes.
HCPLive
SEPTEMBER 4, 2024
This August 2024 month in review spotlights HCPLive’s top coverage of hepatic pipeline news and recent research in liver disease, HCV, and more.
Journal of Cardiothoracic Surgery
SEPTEMBER 4, 2024
To analyze the influencing factors of postoperative thrombocytopenia in critically ill patients with heart disease and construct a nomogram prediction model.
HCPLive
SEPTEMBER 4, 2024
This month in review highlights MDMA-assisted therapy coverage, experiences with zuranolone a year after its approval, and early positive data on potential treatments.
Journal of Cardiothoracic Surgery
SEPTEMBER 4, 2024
Cardiac fibromas are extremely rare in adults. The preferred treatment is surgical resection, but antiarrhythmic medications or heart transplantation have also been used previously. The cardiac imaging, partic.
HCPLive
SEPTEMBER 4, 2024
This Month in Review summarizes some of the most significant stories covered in the month of August in the pulmonary health space, including new research and FDA news.
HeartRhythm
SEPTEMBER 4, 2024
Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are comorbid conditions that are increasingly prevalent and have a high socioeconomic burden. This article discusses their shared pathophysiology, focusing on the triad of hypertension, obesity, and aging.We highlight the misperception that pharmacologic heart rate lowering is beneficial, which has resulted in an overprescription of beta-blockers in HFpEF and AF.
HCPLive
SEPTEMBER 4, 2024
This August 2024 month in review highlights new recommendations from the USPSTF, FDA approval of a treatment for chronic GVHD, and Phase 2 data for severe HDFN.
HeartRhythm
SEPTEMBER 4, 2024
Transthyretin cardiac amyloidosis (ATTR-CA) is the most common type of amyloid cardiomyopathy which frequently presents with cardiac arrythmias. Recent data suggest that sodium-glucose contransporter-2 inhibitors (SGLT2i) may mitigate development of cardiac arrythmias in patients with heart failure with preserved ejection fraction and patients with ischemic heart disease [1].
HCPLive
SEPTEMBER 4, 2024
The biosimilars month in review highlights recent data demonstrating clinical equivalence and efforts to improve their access.
American College of Cardiology
SEPTEMBER 4, 2024
In this week’s View, Dr. Eagle looks at the kidney and cardiovascular effectiveness of SGLT2 inhibitors versus GLP-1 receptor agonists in type 2 diabetes. He then explores the prognostic ability of diffusion-weighted brain MRI lesions after TAVR.
HCPLive
SEPTEMBER 4, 2024
The FDA approved neffy for treating severe allergic reactions in people over 33 kg in August 2024.
American College of Cardiology
SEPTEMBER 4, 2024
What is the role of cardiac magnetic resonance imaging (cMRI) with extracellular volume (ECV) mapping in systemic light chain (AL) amyloidosis compared with serum biomarkers and echocardiography?
The American Journal of Cardiology
SEPTEMBER 4, 2024
Publication date: Available online 4 September 2024 Source: The American Journal of Cardiology Author(s): Marcos García-Guimarães, Manel Sabaté, Ignacio Cruz-González, Ernesto Valero, Teresa Bastante, Fernando Alfonso, investigators of the Spanish Registry on Spontaneous Coronary Artery Dissection
NEJM Journal Watch - Cardiology
SEPTEMBER 4, 2024
In a multicenter randomized trial, edoxaban monotherapy reduced nonfatal major and clinically relevant nonmajor bleeding without excess risk for ischemic events.
American College of Cardiology
SEPTEMBER 4, 2024
Did baseline or on-treatment triglyceride concentration alter the clinical benefit of alirocumab in the ODYSSEY OUTCOMES trial?
NEJM Journal Watch - Cardiology
SEPTEMBER 4, 2024
The nonsteroidal mineralocorticoid receptor antagonist improved this population's rate of worsening heart failure events in a randomized trial.
DAIC
SEPTEMBER 4, 2024
tim.hodson Wed, 09/04/2024 - 15:34 Aug. 29, 2024 – Jupiter Endovascular, Inc., recently announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption application for the SPIRARE II U.S. pivotal study (NCT06576427). The pivotal trial will study the Vertex Pulmonary Embolectomy System, which incorporates Jupiter’s Endoportal Control platform technology into an endovascular procedure intended to treat Acute Pulmonary Embolism (PE) with an unprece
NEJM Journal Watch - Cardiology
SEPTEMBER 4, 2024
The RNA silencer reduced the risk for death and cardiovascular events in both hereditary and wild-type disease.
Expert insights. Personalized for you.
145 
Let's personalize your content